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Abstract
Background A majority of older adults in the United States (US) use prescription medications. Comprehensive populationlevel approaches to examine medication safety, effectiveness, and costs among older adults are needed.
Objectives The objectives of this study were to develop a framework of quality measures spanning the domains of safety, effectiveness, and efficiency of prescription medication use among older adults, and to apply those measures using pharmacy claims data.
Methods We performed a retrospective study among adults age 65 years and older of a US East Coast state who filled at
least one prescription from a particular pharmacy chain during 2016 (N = 99,056). Firstly, we performed an environmental
scan to identify quality measures and potentially relevant measures addressing prescription medication use. These measures
were reviewed and rated by local geriatric pharmacotherapy experts. After evaluating feasibility, evidence, and relevance,
a total of 19 measures representing the domains of safety (n = 7), effectiveness (n = 7), and efficiency (n = 5) were identified. These measures were then applied to an older adult population using prescription data for the year 2016 provided by
a national pharmacy chain. All measures were configured such that a score of 100% corresponded to optimal performance.
Results For the domain of safety, 12.8% of patients received a benzodiazepine chronically, 23.6% received central nervous system
depressants, 16.7% received fluoroquinolones as first-line antibiotic therapy, and 21.9% of those who were prescribed opioids
received them in excessive quantities. For the domain of effectiveness, one-fourth of the diabetes patients did not receive statins
and angiotensin-acting medications, while 18.0% were not adherent to oral anticoagulant medications and 54% were not adherent to
respiratory inhalers. For the domain of efficiency, 12.0% of the patients received prescriptions from five or more unique prescribers.
Overall, 85.7%, 76.1%, and 87.9% of the older adults showed safe, effective, and efficient prescription medication use, respectively.
Conclusion A novel approach to comprehensively examine the quality of medication use among older adults using prescription claims data is provided in our study. A considerable proportion of the older adults in our study received safe, effective,
and efficient prescription medications. However, within each domain, several opportunities for improving the alignment of
prescription medication use with current recommendations were identified.
Key Points
This project was presented at the Academy of Managed Care
Pharmacy (AMCP) Managed Care and Specialty Pharmacy 2018
Annual Meeting, Boston, MA, USA.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s40801-019-00162-x) contains
supplementary material, which is available to authorized users.
* Ami Vyas
avyas@uri.edu
1

Department of Pharmacy Practice, College of Pharmacy,
University of Rhode Island, 7 Greenhouse Road, Kingston,
RI 02881, USA

A novel approach/measurement framework to comprehensively assess safe, effective, and efficient prescription medication use among older adults using pharmacy
claims data is presented.
Overall, 14%, 24%, and 12% of older adults did not show
safe, effective, and efficient prescription medication use,
respectively.
Many opportunities for quality improvement within
the domains of safety, effectiveness, and efficiency of
prescription medication use among older adults were
identified.
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1 Introduction
Most older adults in the United States (US) utilize prescription medication, and approximately 40% are prescribed five or more medications [1]. While medication
is intended to extend life or improve quality of life, its
adverse effects can increase morbidity and mortality [2].
Conversely, optimal health outcomes are unrealized when
patients fail to receive or to adhere to their medications.
Additionally, medication cost is an increasing concern
confronting patients and the health system. Comprehensive population-level approaches to assess and improve
medication safety, effectiveness, and efficiency among
older adults are needed, particularly in the US, where care
fragmentation and lack of effective care coordination can
lead to medication misuse and underuse.
Performance measurement is integral to quality improvement. Measures addressing medication use among older
adults have been developed by several entities. Foremost,
the Pharmacy Quality Alliance (PQA) has developed a
range of quality measures of prescription medication utilization, including measures addressing medication safety and
patient adherence [3]. The US Medicare program provides a
privately administered prescription drug benefit, and has
developed a star rating system for evaluating quality among
drug plan sponsors, using a scheme that includes several of
the PQA’s measures. Other prominent efforts to evaluate
the quality of medication use among older adults include
the Assessing Care of Vulnerable Elders (ACOVE) initiative [4, 5] and the Beers criteria [6]. The ACOVE measures
assess the quality of medication use across 22 health conditions [4, 5]. The Beers criteria for potentially inappropriate
medication use in older adults identifies higher-risk medications that should generally be avoided overall, or avoided or
dose adjusted among particular patients [6]. Other notable
efforts include the Medication Appropriateness Index (MAI)
[7] and the START/STOPP criteria [8].
There are shortcomings to performance measurement. It
is challenging to scale patient-level approaches to screen
populations, particularly those that rely upon reviews of
medication lists or patient interviews. For measures that
utilize administrative claims data, calculating measure
rates often requires the integration of pharmacy and medical databases, and can involve complex measure specifications. Moreover, given the breadth of medication use across
the myriad health conditions that are prevalent among older
adults, it is unlikely that any sole measure will have a dramatic impact on population health outcomes.
We envisioned a quality measurement framework
addressing medication use among older adults, aligned with
the core domains for health technology assessment of safety,
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effectiveness, and cost (efficiency), comprised of measures
that can be calculated using pharmacy data solely. While
pharmacy claims data lack information about medical diagnoses and procedures, there are many health conditions that
can be identified with acceptable specificity according to the
medication prescribed. We sought an approach that would
simplify the complexity associated with analysis of integrated medical, hospital, pharmacy and eligibility data common to many performance measures. We sought to identify
or develop quality measures of medication use among older
adults derived from pharmacy claims, and to apply these
measures to determine their suitability for population-level
analyses. This study presents our S–E–E (Safety–Effectiveness–Efficiency) measurement framework and describes its
application using pharmacy data for a population of older
adults.

2 Methods
The first phase of the two-phase study was to identify or
develop measures relevant to our purpose; the second phase
involved applying these measures to calculate results, overall
and according to patient characteristics.
The process of identifying suitable quality measures
involved a targeted search of the published literature,
identifying measures currently used with the US healthcare system, and brainstorming ideas for new measures
with geriatric pharmacotherapy experts from our institution. A targeted literature review was performed by querying PubMed using the search terms “Beers,” “ACOVE,”
and “START/STOPP,” as informed by the authors’ prior
awareness of these efforts. This search yielded reviews
of these quality measurement initiatives and other efforts
described in their reference lists that were then examined for their relevance to older adults and applicability to pharmacy claims data. We also reviewed extant
measures cataloged in the National Quality Measures
Clearinghouse, developed by the US Agency for Healthcare Research and Quality (AHRQ). Additional candidate measures were brainstormed by the research team,
drawing from their experience in pharmacoepidemiologic
research (e.g., awareness of relevant US Food and Drug
Administration alerts and clinical practice guidelines).
Our measure review was limited to US sources. The
candidate measures identified through these steps were
then reviewed by three clinical geriatric pharmacotherapy experts who rated the dimensions of each candidate
measure as “Yes,” “No,” or “Uncertain” according to (1)
feasibility of adaptation to pharmacy claims data, (2)
whether the measure was evidence-based, and (3) whether
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the measure was applicable to older adults. From the 42
candidate measures identified, 19 were selected by all
reviewers as a “Yes” for all three of these dimensions.
These spanned the domains of safety (n = 7), effectiveness
(n = 7), and efficiency (n = 5) (Table S1 in the Electronic
supplementary material, ESM). The measures were configured so that a score of 100% indicated optimal performance. For example, for a safety measure about avoiding the chronic use of benzodiazepines, we determined
the proportion of older adults without ≥ 60 days’ supply
of benzodiazepines during a measurement year, where
100% indicated optimal performance for that measure.
Additionally, the observations within each domain were
aggregated to determine an overall average score representing the total number of opportunities to avoid a quality problem for each domain.
The measures were operationally defined by the project
team and pilot tested using pharmacy data provided by a
national pharmacy chain. This data source included all
older adults (age 65 or older) residing in an East Coast
state who received at least one medication dispensed by
that pharmacy chain during 2016. Medication attributes
were identified using National Drug Codes. Where relevant, study eligibility criteria included the requirement
that patients had received at least one dispensing of any
medication within the first and last quarters of the measurement year. This criterion was intended to increase the
likelihood that the study patients continued to receive
their medication from the same pharmacy system that
provided the data. Measure numerators and denominators and associated specifications were defined in a narrative document which guided the development of the
analysis plan.
We excluded patients who received cancer medications,
as many of our measures were not intended for end-of-life
care. Patient demographics included age, gender, region of
the state from which the prescription was dispensed, and
payment type. We also identified the top five medical provider groups in the state by patient population, and attributed patients to these groups using a deidentified National
Provider Identifier code. These groups represented leading medical practice organizations within the state. For
the variables defining region, payment type, and provider
group, the most frequent observation was used.
Descriptive statistics included patient age, gender,
region, and payment type. Confidence intervals for
the measures were derived from the standard error and
denominator size. We performed a multivariable logistic
regression analysis for each measure to determine if results
differed significantly according to covariates. Statistical
analyses were conducted using the software SAS 9.4 (SAS
Institute Inc., Cary, North Carolina).

3 Results
3.1 Quality Measures
Detailed specifications of the S–E–E measures are
included in Table S1 of the ESM. Seven measures
addressed medication safety—avoiding the chronic use of
benzodiazepines or central nervous system (CNS) depressants, avoiding the concurrent use of nonsteroidal antiinflammatory medications (NSAIDS) and anticoagulants,
avoiding the concurrent use of anticholinergic medications
with anti-dementia medications, avoiding the use of fluoroquinolones as initial therapy, avoiding the chronic use
of opioids after the initial opioid prescription, and avoiding selected high-risk medications. The high-risk medications included a condensed version of medications listed
in the Beers and the Healthcare Effectiveness Data and
Information Set criteria, deemed by our team to represent medications that present higher risk than therapeutic
alternatives (e.g., first-generation antihistamines, tertiary
tricyclic antidepressants; see Table S2 of the ESM for a
complete listing).
The domain of effectiveness included five measures
addressing patient adherence and two measures addressing the use of evidence-based medications in diabetes. One
additional measure was tested that addressed the prioritization of recommended medications for hypertension: avoiding alpha- and beta-adrenergic blockers in the absence of
compelling comorbidities. This measure was eventually
abandoned due to its complexity. The effectiveness measures of patient adherence addressed the following chronic
therapies: direct oral anticoagulant (DOAC) medications,
oral antidiabetic medications, antidepressants, statins, and
maintenance respiratory inhalers. Adherence was specified using a medication possession ratio (MPR) approach.
We considered patients to be adherent if MPR was 0.8
or higher, indicating that the patient had medication supplied for at least 80% of the days between the first prescription of the relevant medication and the last day of
the measurement year. A MPR of 0.8 or higher is a widely
used threshold of medication adherence [9]. The measures
of evidence-based medication use in diabetes identified
patients who received at least one dispensing for an oral
or injectable diabetes medication during 2016. Among this
group, we identified the proportion who also received at
least one dispensing for (1) a statin medication and (2) an
angiotensin-acting medication.
The measures within the domain of efficiency addressed
health system use and the utilization of generic medications.
The former included measures determining the patient’s total
number of prescribers and the total number of medications
prescribed. We set a threshold of five or more prescribers
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as indicating a higher risk of medication-related problems
associated with care fragmentation, and the patient’s receipt
of an average of ten or more medications per month as a
somewhat arbitrary threshold for a patient receiving a substantial number of medications which might trigger the need
for regimen review. We also included measures of generic
medication use, measured as an overall generic utilization
rate, and including generic utilization rates for medications
for diabetes and depression. Most US states either mandate
or permit the substitution of generic formulations, yet opportunities may exist to increase the use of lower cost generics
as alternatives to newer and higher-priced brand-name medications within the same therapeutic class when clinically
appropriate.
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Table 1  Study population:
community-dwelling older
adults from an east coast state
who filled prescriptions in 2016
(N = 99,056)

3.2 Quality Measures in the Patient Population
The measures were applied to the eligible older population
(N = 99,056). A majority of the patients were aged > 70 years
(60.5%), female (56.5%), and had public insurance (Medicare)
identified as the primary payment type (75.9%) (Table 1).
Results indicated a range of opportunities to improve
medication use among older adults (Fig. 1). For the domain
of safety, 12.8% of patients received a benzodiazepine chronically, while 23.6% received chronic CNS depressant medication. Additionally, among all new antibiotic prescriptions
(no previous antibiotic prescription in the previous 60 days),
fluoroquinolones represented 16.7% of dispensings. The
safety measure addressing opioid use determined the number
of patients with at least one opioid prescription who received
at least 200 opioid dosage units, and 21.9% were found to
have received at least this amount.
Within the domain of effectiveness, 71.7% of patients
were adherent to DOAC, 82.8% to antidiabetic medications,
76.3% to antidepressants, 80.4% to cholesterol medications,
and 46.1% to chronic respiratory inhalers. Approximately
three of four patients with medications for diabetes also
received at least one dispensing of a statin (74.4%) and at
least one dispensing of an angiotensin-acting medication
(73.6%). For the domain of efficiency, 78.3% of patients
received prescriptions from less than five unique prescribers, and 93.3% utilized less than an average of ten medications per month. Additionally, among all of the dispensings
that occurred in 2016, 87.4% were for generic medications,
88.7% of the dispensings for antidiabetic medications were
for generics, while 98.7% of the dispensings for antidepressants were for generic products.
The aggregated results indicated that, overall, 85.7%,
76.1%, and 87.9% of the study population showed safe,
effective, and efficient prescription medication use, respectively (Fig. 1).

Characteristics
Age (years)
65–70
71–79
80+
Gender
Female
Male
Region
A
B
C
D
E
Payment type
Cash
Commercial
Medicaid
Medicare

n

%

39,089
36,944
23,023

39.5
37.3
23.2

55,937
43,089

56.5
43.5

48,293
6388
17,750
9754
16,871

48.8
6.4
17.9
9.8
17.0

6290
16,354
1267
75,154

6.3
16.5
1.3
75.9

n number of patients within
each subgroup

3.3 Predictors of Optimal Performance
3.3.1 Safety
Measure rates were generally similar regardless of patient
age group and gender, although some significant differences were identified. Compared to older adults aged
65–70 years, those who were > 80 years old had significantly higher odds of avoiding benzodiazepines [adjusted
odds ratio (AOR) = 1.21, 95% confidence interval (CI)
1.13–1.29] and avoiding the use of CNS depressant agents
(AOR = 1.21, 95% CI 1.15–1.28) (Table 2). Older adults
aged > 80 years with dementia were almost twice as
likely to avoid anticholinergics compared with those aged
65–70 years (AOR = 1.98, 95% CI 1.05–3.72). Additionally,
patients above 70 years of age were significantly more likely
to avoid current NSAIDs and anticoagulants (AORs were
1.45 and 2.17 for the 71–80 years group and those above
80 years of age, respectively), and also more likely to avoid
high risk medications. Older adults aged > 70 years were
significantly less likely to avoid receiving fluoroquinolones
as initial therapy compared to those 65–70 years of age
(AOR = 0.79). Compared to males, females were significantly less likely to avoid benzodiazepines (AOR = 0.55)
or CNS depressants (AOR = 0.68), fluoroquinolones as initial therapy (AOR = 0.81), or opioids in larger quantities
(AOR = 0.83).
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100%
98.7%
88.7%

87.4%

78.3%

73.6%

74.4%

80.4%

76.3%

82.8%
71.7%

60%

93.3%

94.9%
78.1%

76.4%

70%

83.3%

80%

89.1%

96.5%

90%
87.2%

Fig. 1  Overall results for the
S–E–E quality measurement
framework addressing safety,
effectiveness, and efficiency of
medication use among older
adults

50%
46.1%

40%
30%
20%
10%
0%

S1 S2 S3 S4 S5 S6 S7 E1 E2 E3 E4 E5 E6 E7 C1 C2 C3 C4 C5

Safe (S)

Effective (E)

Efficient (C)

Overall Results: 85.7%

Overall Results: 76.1%

Overall Results: 87.9%

Avoid use of:
S1. Benzodiazepines
S2. CNS depressants
S3. NSAIDS, if using
anticoagulants
S4. Anticholinergics in dementia
S5. Fluoroquinolones as initial
therapy
S6. Chronic opioids
S7. High-risk / potentially
inappropriate drugs

Patient adherence to:
E1. Direct anticoagulants
E2. Diabetes medications
E3. Depression medications
E4. Cholesterol medications
E5. Respiratory inhalers

Health system use:
C1. Limit number of
prescribers
C2. Avoid use of 10 or more
medications in a month

Evidence-based therapies:
E6. Statin use in diabetes
E7. ACEI/ARB use in diabetes

Use of generics:
C3. Overall
C4. Diabetes medications
C5. Antidepressants

CNS=Central Nervous System; ACEI=Angiotensin Converting Enzyme Inhibitors; ARB=Angiotensin II Receptor Antagonists;
NSAIDs=Non-Steroidal Anti-Inflammatory Drugs

3.3.2 Effectiveness

3.3.3 Efficiency

Compared to older adults aged 65–70 years, those aged
71–80 years were significantly more likely to adhere to
oral antidiabetic (AOR = 1.16, 95% CI 1.02–1.32) and
cholesterol (AOR = 1.08, 95% CI 1.02–1.16) medications,
and those aged > 80 years were more likely to adhere to
cholesterol medications (AOR = 1.18, 95% CI 1.10–1.28)
(Table 3). Among patients with diabetes, those in the
71–80 years age group were significantly more likely to
receive a prescription of a statin (AOR = 1.16) compared
to those aged 65–70 years. However, those above 80 years
of age were significantly less likely to receive a prescription for a statin (AOR = 0.86, 95% CI 0.77–0.99) or an
ACEI/ARB (AOR = 0.79, 95% CI 0.71–0.89). Females
were significantly less likely to adhere to cholesterol medications than males (AOR = 0.89, 95% CI 0.84–0.95).

Compared to older adults aged 65–70 years, those aged
> 70 years were significantly less likely to have fewer (≤ 5)
prescribers (AORs were 0.82 and 0.92 for the 71–80 years
group and for those above 80 years, respectively) (Table 4).
Additionally, females were significantly less likely to avoid
receiving at least ten medications than males (AOR = 0.84,
95% CI 0.76–0.94).

4 Discussion
Given the ubiquity of medication use among older adults
and its substantial potential for both benefit and harm,
assessing the quality of medication use is vital to optimize
patient health outcomes. At the provider level, this task is
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Table 2  Adjusted odds of desired performance for medication safety quality measures, shown as odds ratio (95% confidence interval)

Age category
(ref = 65–70 years)
71–80
81+
Gender (ref = male)
Female
Region (ref = A)
B
C
D
E

S4. Avoid
anticholinergic drugs in
dementia

S7. Avoid
S5. Avoid fluo- S6. Avoid
roquinolone as large quantities higher-risk/inappropriate drugs
initial therapy of opioids

1.45 (1.05–
1.99)
2.17 (1.53–
3.07)

1.47 (0.77–
2.83)
1.98 (1.05–
3.72)

0.79 (0.73–
0.86)
0.79 (0.72–
0.86)

1.00 (0.90–
1.11)
1.12 (0.99–
1.27)

1.20 (1.12–1.30)

0.68 (0.65–
0.70)

0.96 (0.73–
1.25)

0.72 (0.49–
1.06)

0.81 (0.75–
0.87)

0.83 (0.76–
0.91)

0.94 (0.86–1.02)

1.09 (1.00–
1.18)
0.93 (0.88–
0.98)
0.96 (0.89–
1.03)
1.04 (0.98–
1.11)

2.14 (1.11–
4.13)
1.37 (0.93–
2.00)
1.50 (0.90–
2.51)
0.95 (0.66–
1.37)

1.51 (0.75–
3.03)
1.53 (0.92–
2.54)
0.83 (0.45–
1.53)
1.40 (0.76–
2.58)

1.11 (0.96–
1.29)
1.16 (1.05–
1.28)
1.28 (1.22–
1.28)
1.15 (1.04–
1.28)

1.00 (0.82–
1.22)
0.97 (0.86–
1.10)
1.15 (0.97–
1.37)
1.33 (1.15–
1.53)

0.90 (0.77–1.06)

S1. Avoid benzodiazepines

S2. Avoid CNS S3. Avoid
depressants
NSAIDs if
using anticoagulants

1.01 (0.96–
1.07)
1.21 (1.13–
1.29)

1.01 (0.96–
1.05)
1.21 (1.15–
1.28)

0.55 (0.53–
0.58)
1.05 (0.85–
1.16)
0.92 (0.86–
0.98)
1.08 (0.99–
1.19)
1.12 (1.03–
1.21)

1.66 (1.50–1.85)

0.78 (0.71–0.86)
0.59 (0.52–0.66)
0.79 (0.71–0.86)

Adjusted for provider group
ref reference, CNS central nervous system, NSAIDs nonsteroidal anti-inflammatory drugs
P < 0.05 for values in bold

Table 3  Adjusted odds of desired performance for medication effectiveness quality measures, shown as odds ratio (95% confidence interval)

Age category
(ref = 65–70 years)
71–80
81+
Gender (ref = male)
Female
Region (ref = A)
B
C
D
E

E7. Use of
ACEI or ARB
if prescribed for
diabetes

E1. 80%
adherence to
anticoagulants

E2. 80% adher- E3. 80% adher- E4. 80%
ence to antide- adherence to
ence to oral
cholesterol
diabetes drugs pressants
medications

E5. 80% adher- E6. Use
ence to respira- of statin if
prescribed for
tory inhalers
diabetes

1.11 (0.87–
1.42)
1.20 (0.92–
1.55)

1.16 (1.02–
1.32)
0.99 (0.85–
1.16)

1.02 (0.93–
1.12)
1.08 (0.97–
1.21)

1.08 (1.02–
1.16)
1.18 (1.10–
1.28)

0.99 (0.86–
1.13)
1.03 (0.88–
1.22)

1.16 (1.05–
1.28)
0.86 (0.77–
0.99)

1.07 (0.97–1.18)

1.13 (0.93–
1.38)

0.91 (0.81–
1.02)

0.98 (0.83–
1.04)

0.89 (0.84–
0.95)

1.05 (0.93–
1.19)

0.94 (0.86–
1.02)

1.07 (0.98–1.16)

1.00 (0.68–
1.47)
1.11 (0.84–
1.46)
1.30 (0.95–
1.80)
1.57 (1.16–
2.12)

1.17 (0.92–
1.49)
1.07 (0.92–
1.24)
0.95 (0.76–
1.19)
1.48 (1.19–
1.84)

1.05 (0.89–
1.24)
1.04 (0.93–
1.16)
1.07 (0.91–
1.26)
0.98 (0.86–
1.11)

1.17 (1.04–
1.31)
1.10 (1.02–
1.19)
1.07 (0.96–
1.19)
1.07 (0.97–
1.17)

0.84 (0.65–
1.09)
1.06 (0.91–
1.25)
0.95 (0.77–
1.18)
0.96 (0.79–
1.17)

1.26 (1.04–
1.52)
0.99 (1.00–
1.11)
0.85 (0.72–
0.99)
0.82 (0.72–
0.93)

0.91 (0.76–1.09)

Adjusted for provider groups
ref reference, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor antagonists
P < 0.05 for values in bold

0.79 (0.71–0.89)

0.87 (0.79–0.99)
0.75 (0.64–0.88)
0.71 (0.63–0.81)
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Table 4  Adjusted odds of desired performance for medication efficiency quality measures, shown as odds ratio (95% confidence interval)
C1. Less than 5 prescribers C2. Less than 10
medications used
Age category
(ref = 65–70 years)
71–80 years
81+ years
Gender (ref = male)
Female
Region (ref = A)
B
C
D
E

0.82 (0.78–0.86)
0.92 (0.87–0.97)

0.90 (0.80–1.01)
1.10 (0.96–1.27)

0.97 (0.93–1.01)

0.84 (0.76–0.94)

1.01 (0.93–1.10)
0.96 (0.91–1.02)
0.81 (0.76–0.87)
0.91 (0.86–0.97)

0.85 (0.71–1.03)
1.09 (0.95–1.25)
1.24 (1.02–1.52)
1.33 (1.12–1.58)

Adjusted for provider groups
Results of regression analyses are not reported for measures C3-C5
that address the utilization of generic medications (overall rate, and
for diabetes and mental health medications) because provider groups
and regions varied with prescription
ref reference
P < 0.05 for values in bold

complicated by a fragmented health care system and often a
lack of physician constancy. Population-level approaches to
evaluate the quality of medication use among older adults
are needed. Although several leading entities incorporate
prescription medication use measures into their quality
improvement efforts, evaluating and improving medication
use among older adults remains a formidable challenge. In
our comprehensive population-level study of the use of prescription medications among older adults, we found considerable room for improvement, with deficits from optimal
performance ranging from 12.1% for the domain of efficiency, 14.3% for the domain of safety, and 23.9% for the
domain of effectiveness.
Several measures stood out in terms of opportunity for
improvement. Within the domain of safety, almost one-fourth
of the study population (76.4%) received at least 60 days’
supply of CNS depressant medication. Bernardy et al. found
that 12% of older veterans with post-traumatic stress disorder concurrently received three or more classes of CNS
depressants [10]. Additionally, we found that women were
less likely than males to avoid CNS depressants, a finding
consistent with that reported by Bernardy et al. [10]. Given
the increased risk of cognitive decline and falls associated
with the use of CNS depressants in older adults [11], our
finding raises concerns about increased potential adverse
events among these patients. We considered it important to
include a measure of opioid utilization in the safety domain.
This measure reflects the ratio of short-term to chronic opioid

utilizers, consistent with the aim that if opioids are prescribed, they should be used as briefly as possible and at the
lowest dosage possible [12]. Furthermore, 13% of the study
population were prescribed benzodiazepines chronically, a
finding generally consistent with that reported in US-based
studies [13–15]. A study conducted among older Medicare
enrollees entering home healthcare services reported that
19% were prescribed a benzodiazepine [13], while another
study reported that the prevalence of benzodiazepine use was
approximately 10% among older veterans [14]. Yet another
study by Maust et al. found that 13% of older adults reported
using benzodiazepines [15]. Our result was substantially
lower than the percentages reported by non-US studies [16,
17]: a Canadian study found that 25% of community-dwelling
older adults used benzodiazepines [16], while a Brazilian
study reported that the prevalence of benzodiazepine use
among older adults was 21–27% [17]. Our finding is potentially alarming given the risks of these medications, which
include cognitive impairment, delirium, falls, and fractures
[18], leading to the recommendation that benzodiazepines
should be avoided in this vulnerable population [6]. Our finding that females were less likely to avoid benzodiazepine use
is consistent with an earlier report [19], indicating that efforts
to reduce benzodiazepine use in this subgroup are needed.
For the domain of effectiveness, the measures of medication adherence indicated that a substantial percentage of
patients do not refill prescriptions regularly. The lowest rate
was among patients utilizing chronic inhalers for respiratory
disease. Poor consistency in the refilling of chronic inhalers
among older adults has been reported previously [20, 21].
Our finding may also suggest that some patients did not have
chronic respiratory illness and were prescribed the inhaler
on a short-term basis. Adherence to DOAC medication was
71.7%, a finding consistent with that reported in a published
study [22]. A slightly higher percentage (76.3%) of the
patients were adherent to antidepressant medications. Placing this result in the context of the literature on adherence
with antidepressants is complicated by the predominance of
research that focuses on treatment persistence in new therapy
initiators only. Such research excludes the majority of patients
who utilize antidepressant medications chronically, and while
these medications may not need to be taken indefinitely, they
should not be taken sporadically, as poor adherence patterns
reveal. We believe that reporting adherence rates among all
patients prescribed antidepressants, not just new therapy initiators, is a better approach. Approximately 80% of the patients
were adherent to antidiabetic medications and cholesterol
medications, underscoring the continuing need to promote
adherence to these vital therapies. In addition, the finding that
approximately one in four patients receiving medication for
diabetes did not also receive a statin or an angiotensin-acting
medication justifies the continued emphasis on these important elements of diabetes care [23–25].
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For the domain of efficiency, we found that 21.7% of
patients filled prescriptions from five or more unique prescribers. Having multiple prescribers has been shown to
increase the risk of adverse drug events [26] and is associated with unnecessary medication use in older adults [27].
Our measure of receiving an average of ten or more medications per month may be considered extreme, as others have
defined polypharmacy as five concurrent medications [28].
Yet, rather than classify a large proportion of patients as
receiving a substantial number of medications, our higher
threshold of at least ten prescribed medications identifies
a smaller percentage of patients (6.7%) who would be at a
higher risk for adverse drug events and associated health
care costs. Measures addressing the utilization of generics
revealed a limited opportunity for improvement. The overall
generic utilization rate of 87.4% indicates that a substantial
proportion of the medications utilized by older adults were
not higher-cost branded products.
In our study, we offer a novel approach to the comprehensive assessment of medication use among older adults, which
can augment other efforts to address quality of medication
use in this population. The Beers criteria is well recognized
as an important guide for prescribers, yet the medications it
includes represent only a portion of all commonly prescribed
medications that have the potential for untoward effects,
while medication cost is beyond its scope [29–31]. The MAI
does not directly address adherence patterns or cost using
claims data [32]. Another notable framework, the START/
STOPP criteria [33], contains a comprehensive validated
array of standards that address inappropriate medication use
and underuse. The START/STOPP criteria are intended for
application in clinical settings, rather than for population-level
analysis using administrative data sources. Many of the quality measures in the ACOVE project address medication use,
yet the measures that can be calculated using administrative
data require medical diagnoses beyond what is available in
pharmacy data. Lastly, the PQA [3] has developed measures
within the domains of adherence, appropriate medication use,
safety, medication therapy management, and quality improvement, and many of their measures address similar dimensions
of medication use to those in our framework. However, we
sought to include only measures that can be reported using
pharmacy claims solely, that address medication use among
older adults exclusively, and can be aggregated to provide a
profile score for each domain of medication use.
Several limitations of our study are important to note. Our
review of relevant measures was restricted to the US; we did
not review relevant quality measures or initiatives from other
nations. We also note that the measures described here should
not be interpreted as explicit criteria. Clinical circumstances
can warrant, for example, the chronic use of benzodiazepines or the need for large quantities of opioid medications.
For instance, among several factors, comorbidities, disease
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severity, physical function, and frailty may affect the quality
of medication use in older adults. Thus, our measures should
only be applied at larger units of analysis and to identify
substantial differences across groups of similar patient populations. Also, measures described here are not universally
accepted criteria. However, we describe a comprehensive
framework that can be applied using prescription medication
pharmacy claims and can examine the quality of prescription medication use in older adults. Additionally, pharmacy
claims data are limited by a lack of information about patient
diagnoses, disease severity, race/ethnicity, household income,
and education, so these factors could not be assessed. Also,
the findings may not be generalized to older adults from a
different US region or pharmacy retailer. Finally, we did not
formally evaluate the reliability and validity of the measures
described in this study. An important next phase of this study
is to determine if patient health outcomes differ according to
the results for each domain. Further validation is warranted
before the wide-scale application of this measurement framework for the purpose of accountability.

5 Conclusion
We provide a novel method to comprehensively evaluate
quality of medication use among older adults using realworld prescription claims data. We found that a majority
of older adults received safe, effective, and efficient prescription medications. However, our results also revealed
a range of opportunities within each domain to better align
medication use with current recommendations. Future
studies are required to ascertain the validity of the measure set considering adverse events, health outcomes, and
healthcare utilization.
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